Effect of Healing Touch on the Experience of Women Undergoing Treatment for Breast Cancer

This study has been completed.
Sponsor:
Collaborator:
Avon Foundation
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT00533780
First received: September 20, 2007
Last updated: June 1, 2010
Last verified: June 2010
  Purpose

To learn what effect, if any, Healing Touch (a gentle, non-invasive form of energy work that promotes relaxation and can help manage the side effects of chemotherapy and radiation), has on physical symptoms, mood, and qualify of life for women undergoing treatment for breast cancer.


Condition Intervention
Breast Cancer
Procedure: Healing Touch

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effect of Healing Touch on the Experience of Women Undergoing Treatment for Breast Cancer

Resource links provided by NLM:


Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Effect Healing Touch has on physical symptoms, mood and quality of life for women undergoing treatment for breast cancer. [ Time Frame: Baseline, 3 months, 6 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 200
Study Start Date: January 2005
Study Completion Date: August 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:- Patients undergoing treatment for breast cancer.

  • Age 18 or over.
  • Participants in Healing Partners Program.

Exclusion Criteria:- Patients not under the care of a physician.

  • Patients not able to come to regular healing touch sessions.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00533780

Locations
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Avon Foundation
Investigators
Principal Investigator: Lynn m Westphal Stanford University
  More Information

No publications provided

Responsible Party: Lynn M Westphal, Stanford University School of Medicine
ClinicalTrials.gov Identifier: NCT00533780     History of Changes
Other Study ID Numbers: BRSADJ0003, 95738, BRSADJ0003
Study First Received: September 20, 2007
Last Updated: June 1, 2010
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases

ClinicalTrials.gov processed this record on August 28, 2014